Loading…
Lobbying Spend
—
Filings
260
Firms Hired
6
Active Period
2007–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Medication Affordability and Patent Integrity Act
2026 · third_quarter · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to drug pricing; Issues related to S. 2658 - Medication Affordability and Patent Integrity Act.
Client expense: — · Firm income: $50,000
Matched citations: S. 2658
Lower Costs, More Transparency Act of 2026
2026 · third_quarter · Firm: DAVE KOLBE CONSULTING
H.R. 9393 (Lower Costs, More Transparency Act of 2026) -In support of the Lower Cost, More Transparency Act as this bill will require hospitals, labs, and image providers to make price information publicly available and will help reign in Pharmacy Benefit Managers (PBMs).
Client expense: — · Firm income: $30,000
Matched citations: H.R. 9393
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2026 · third_quarter · Firm: E3 STRATEGIC CONSULTING GROUP
Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing and price controls, supply chain issues, pharmacy benefit managers transparency issues, intellectual property, trade, and employment issues, 340B program, generally; S. 1040, Drug Competition Enhancement Act; H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 4317, PBM Reform Act of 2025; H.R. 5256, 340B ACCESS Act"; S. 3345, "PBM Price Transparency and Accountability Act"; S. 2658, Medication Affordability and Patent Integrity Act; S. 1414, Expedited Access to Biosimilars Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1492
PBM Reform Act of 2025
2026 · third_quarter · Firm: E3 STRATEGIC CONSULTING GROUP
Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing and price controls, supply chain issues, pharmacy benefit managers transparency issues, intellectual property, trade, and employment issues, 340B program, generally; S. 1040, Drug Competition Enhancement Act; H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 4317, PBM Reform Act of 2025; H.R. 5256, 340B ACCESS Act"; S. 3345, "PBM Price Transparency and Accountability Act"; S. 2658, Medication Affordability and Patent Integrity Act; S. 1414, Expedited Access to Biosimilars Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 4317
Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing and price controls, supply chain issues, pharmacy benefit managers transparency issues, intellectual property, trade, and employment issues, 340B program, generally; S. 1040, Drug Competition Enhancement Act; H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 4317, PBM Reform Act of 2025; H.R. 5256, 340B ACCESS Act"; S. 3345, "PBM Price Transparency and Accountability Act"; S. 2658, Medication Affordability and Patent Integrity Act; S. 1414, Expedited Access to Biosimilars Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 5256
Drug Competition Enhancement Act
2026 · third_quarter · Firm: E3 STRATEGIC CONSULTING GROUP
Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing and price controls, supply chain issues, pharmacy benefit managers transparency issues, intellectual property, trade, and employment issues, 340B program, generally; S. 1040, Drug Competition Enhancement Act; H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 4317, PBM Reform Act of 2025; H.R. 5256, 340B ACCESS Act"; S. 3345, "PBM Price Transparency and Accountability Act"; S. 2658, Medication Affordability and Patent Integrity Act; S. 1414, Expedited Access to Biosimilars Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 1040
Expedited Access to Biosimilars Act
2026 · third_quarter · Firm: E3 STRATEGIC CONSULTING GROUP
Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing and price controls, supply chain issues, pharmacy benefit managers transparency issues, intellectual property, trade, and employment issues, 340B program, generally; S. 1040, Drug Competition Enhancement Act; H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 4317, PBM Reform Act of 2025; H.R. 5256, 340B ACCESS Act"; S. 3345, "PBM Price Transparency and Accountability Act"; S. 2658, Medication Affordability and Patent Integrity Act; S. 1414, Expedited Access to Biosimilars Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 1414
Medication Affordability and Patent Integrity Act
2026 · third_quarter · Firm: E3 STRATEGIC CONSULTING GROUP
Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing and price controls, supply chain issues, pharmacy benefit managers transparency issues, intellectual property, trade, and employment issues, 340B program, generally; S. 1040, Drug Competition Enhancement Act; H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 4317, PBM Reform Act of 2025; H.R. 5256, 340B ACCESS Act"; S. 3345, "PBM Price Transparency and Accountability Act"; S. 2658, Medication Affordability and Patent Integrity Act; S. 1414, Expedited Access to Biosimilars Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 2658
PBM Price Transparency and Accountability Act
2026 · third_quarter · Firm: E3 STRATEGIC CONSULTING GROUP
Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing and price controls, supply chain issues, pharmacy benefit managers transparency issues, intellectual property, trade, and employment issues, 340B program, generally; S. 1040, Drug Competition Enhancement Act; H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 4317, PBM Reform Act of 2025; H.R. 5256, 340B ACCESS Act"; S. 3345, "PBM Price Transparency and Accountability Act"; S. 2658, Medication Affordability and Patent Integrity Act; S. 1414, Expedited Access to Biosimilars Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 3345
Medication Affordability and Patent Integrity Act
2026 · second_quarter · Firm: TIBER CREEK GROUP
Issues related to IP protection under Bayh Dole; Issues related to implementation of drug pricing and reimbursement for prescription drugs related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to drug pricing; Issues related to S. 2658 - Medication Affordability and Patent Integrity Act.
Client expense: — · Firm income: $50,000
Matched citations: S. 2658
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2026 · second_quarter · Firm: E3 STRATEGIC CONSULTING GROUP
Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing and price controls, supply chain issues, pharmacy benefit managers transparency issues, intellectual property, trade, and employment issues, 340B program, generally; S. 1040, Drug Competition Enhancement Act; H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 4317, PBM Reform Act of 2025; H.R. 5256, 340B ACCESS Act"; S. 3345, "PBM Price Transparency and Accountability Act"; S. 2658, Medication Affordability and Patent Integrity Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1492
PBM Reform Act of 2025
2026 · second_quarter · Firm: E3 STRATEGIC CONSULTING GROUP
Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing and price controls, supply chain issues, pharmacy benefit managers transparency issues, intellectual property, trade, and employment issues, 340B program, generally; S. 1040, Drug Competition Enhancement Act; H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 4317, PBM Reform Act of 2025; H.R. 5256, 340B ACCESS Act"; S. 3345, "PBM Price Transparency and Accountability Act"; S. 2658, Medication Affordability and Patent Integrity Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 4317
Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing and price controls, supply chain issues, pharmacy benefit managers transparency issues, intellectual property, trade, and employment issues, 340B program, generally; S. 1040, Drug Competition Enhancement Act; H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 4317, PBM Reform Act of 2025; H.R. 5256, 340B ACCESS Act"; S. 3345, "PBM Price Transparency and Accountability Act"; S. 2658, Medication Affordability and Patent Integrity Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 5256
Drug Competition Enhancement Act
2026 · second_quarter · Firm: E3 STRATEGIC CONSULTING GROUP
Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing and price controls, supply chain issues, pharmacy benefit managers transparency issues, intellectual property, trade, and employment issues, 340B program, generally; S. 1040, Drug Competition Enhancement Act; H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 4317, PBM Reform Act of 2025; H.R. 5256, 340B ACCESS Act"; S. 3345, "PBM Price Transparency and Accountability Act"; S. 2658, Medication Affordability and Patent Integrity Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 1040
Medication Affordability and Patent Integrity Act
2026 · second_quarter · Firm: E3 STRATEGIC CONSULTING GROUP
Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing and price controls, supply chain issues, pharmacy benefit managers transparency issues, intellectual property, trade, and employment issues, 340B program, generally; S. 1040, Drug Competition Enhancement Act; H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 4317, PBM Reform Act of 2025; H.R. 5256, 340B ACCESS Act"; S. 3345, "PBM Price Transparency and Accountability Act"; S. 2658, Medication Affordability and Patent Integrity Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 2658
PBM Price Transparency and Accountability Act
2026 · second_quarter · Firm: E3 STRATEGIC CONSULTING GROUP
Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing and price controls, supply chain issues, pharmacy benefit managers transparency issues, intellectual property, trade, and employment issues, 340B program, generally; S. 1040, Drug Competition Enhancement Act; H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 4317, PBM Reform Act of 2025; H.R. 5256, 340B ACCESS Act"; S. 3345, "PBM Price Transparency and Accountability Act"; S. 2658, Medication Affordability and Patent Integrity Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 3345
PROFITS OVER PATIENTS: THE PBM BUSINESS MODEL UNDER SCRUTINY" - Support comprehensive reform that addresses the entire healthcare supply chain. PBM practices drive up out-of-pocket costs for union members and working families. 340B In Managing Healthcare Costs for Taft-Hartley Plans - Federal reforms would ensure the 340B program supports patient care without shifting costs on multi=employer health plans. Pending legislation would tighten rules on outpatient versus inpatient pricing, limit certain administrative costs, increase transparency, and add new requirements for 340B hospitals. S. 2658 Medication Affordability and Patent Integrity Act - Opposition to S. 2658 as there is no evidence of a systemic issue needing to be addressed by enacting such burdensome requirements for innovator companies, as well as for the USPTO. S.2305 Biosimilar Red Tape Elimination Act - Opposing S. 2305 as the bill is unnecessary. FDA already has the authority to approve biosimilar interchangeability without requiring switching studies and is exercising that authority in recently approved interchangeable biosimilars. Eliminating these standards will do nothing to improve patient access to biosimilars if they are excluded from coverage by PBMs and Health plans. S. 3014 Ensuring Timely Access to Generics Act of 2025 - Opposing S. 3014 as it would amend Section 505(q) of the FDCA to grant FDA authority to summarily deny 505(q) citizen petitions (about approval of generics, biosimilars, and 505(b)(2) applications) if the Agency determines either that the petition was submitted with the primary purpose of delay or does not on its face raise valid scientific or regulatory issues. The bill is unnecessary given FDA's existing authorities as well as FDA guidance.
Client expense: — · Firm income: $30,000
Matched citations: S. 2305, S.2305
Medication Affordability and Patent Integrity Act
2026 · second_quarter · Firm: DAVE KOLBE CONSULTING
PROFITS OVER PATIENTS: THE PBM BUSINESS MODEL UNDER SCRUTINY" - Support comprehensive reform that addresses the entire healthcare supply chain. PBM practices drive up out-of-pocket costs for union members and working families. 340B In Managing Healthcare Costs for Taft-Hartley Plans - Federal reforms would ensure the 340B program supports patient care without shifting costs on multi=employer health plans. Pending legislation would tighten rules on outpatient versus inpatient pricing, limit certain administrative costs, increase transparency, and add new requirements for 340B hospitals. S. 2658 Medication Affordability and Patent Integrity Act - Opposition to S. 2658 as there is no evidence of a systemic issue needing to be addressed by enacting such burdensome requirements for innovator companies, as well as for the USPTO. S.2305 Biosimilar Red Tape Elimination Act - Opposing S. 2305 as the bill is unnecessary. FDA already has the authority to approve biosimilar interchangeability without requiring switching studies and is exercising that authority in recently approved interchangeable biosimilars. Eliminating these standards will do nothing to improve patient access to biosimilars if they are excluded from coverage by PBMs and Health plans. S. 3014 Ensuring Timely Access to Generics Act of 2025 - Opposing S. 3014 as it would amend Section 505(q) of the FDCA to grant FDA authority to summarily deny 505(q) citizen petitions (about approval of generics, biosimilars, and 505(b)(2) applications) if the Agency determines either that the petition was submitted with the primary purpose of delay or does not on its face raise valid scientific or regulatory issues. The bill is unnecessary given FDA's existing authorities as well as FDA guidance.
Client expense: — · Firm income: $30,000
Matched citations: S. 2658
Ensuring Timely Access to Generics Act of 2025
2026 · second_quarter · Firm: DAVE KOLBE CONSULTING
PROFITS OVER PATIENTS: THE PBM BUSINESS MODEL UNDER SCRUTINY" - Support comprehensive reform that addresses the entire healthcare supply chain. PBM practices drive up out-of-pocket costs for union members and working families. 340B In Managing Healthcare Costs for Taft-Hartley Plans - Federal reforms would ensure the 340B program supports patient care without shifting costs on multi=employer health plans. Pending legislation would tighten rules on outpatient versus inpatient pricing, limit certain administrative costs, increase transparency, and add new requirements for 340B hospitals. S. 2658 Medication Affordability and Patent Integrity Act - Opposition to S. 2658 as there is no evidence of a systemic issue needing to be addressed by enacting such burdensome requirements for innovator companies, as well as for the USPTO. S.2305 Biosimilar Red Tape Elimination Act - Opposing S. 2305 as the bill is unnecessary. FDA already has the authority to approve biosimilar interchangeability without requiring switching studies and is exercising that authority in recently approved interchangeable biosimilars. Eliminating these standards will do nothing to improve patient access to biosimilars if they are excluded from coverage by PBMs and Health plans. S. 3014 Ensuring Timely Access to Generics Act of 2025 - Opposing S. 3014 as it would amend Section 505(q) of the FDCA to grant FDA authority to summarily deny 505(q) citizen petitions (about approval of generics, biosimilars, and 505(b)(2) applications) if the Agency determines either that the petition was submitted with the primary purpose of delay or does not on its face raise valid scientific or regulatory issues. The bill is unnecessary given FDA's existing authorities as well as FDA guidance.
Client expense: — · Firm income: $30,000
Matched citations: S. 3014
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2026 · first_quarter · Firm: E3 STRATEGIC CONSULTING GROUP
Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, supply chain issues, pharmacy benefit managers transparency issues, Intellectual property, trade, and employment issues, 340B program, generally; S. 1040, Drug Competition Enhancement Act; H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 4317, PBM Reform Act of 2025; H.R. 5256, 340B ACCESS Act;" S. 3345 - "PBM Price Transparency and Accountability Act."
Client expense: — · Firm income: $60,000
Matched citations: H.R.1492
PBM Reform Act of 2025
2026 · first_quarter · Firm: E3 STRATEGIC CONSULTING GROUP
Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, supply chain issues, pharmacy benefit managers transparency issues, Intellectual property, trade, and employment issues, 340B program, generally; S. 1040, Drug Competition Enhancement Act; H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 4317, PBM Reform Act of 2025; H.R. 5256, 340B ACCESS Act;" S. 3345 - "PBM Price Transparency and Accountability Act."
Client expense: — · Firm income: $60,000
Matched citations: H.R. 4317
Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, supply chain issues, pharmacy benefit managers transparency issues, Intellectual property, trade, and employment issues, 340B program, generally; S. 1040, Drug Competition Enhancement Act; H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 4317, PBM Reform Act of 2025; H.R. 5256, 340B ACCESS Act;" S. 3345 - "PBM Price Transparency and Accountability Act."
Client expense: — · Firm income: $60,000
Matched citations: H.R. 5256
Drug Competition Enhancement Act
2026 · first_quarter · Firm: E3 STRATEGIC CONSULTING GROUP
Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, supply chain issues, pharmacy benefit managers transparency issues, Intellectual property, trade, and employment issues, 340B program, generally; S. 1040, Drug Competition Enhancement Act; H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 4317, PBM Reform Act of 2025; H.R. 5256, 340B ACCESS Act;" S. 3345 - "PBM Price Transparency and Accountability Act."
Client expense: — · Firm income: $60,000
Matched citations: S. 1040
PBM Price Transparency and Accountability Act
2026 · first_quarter · Firm: E3 STRATEGIC CONSULTING GROUP
Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, supply chain issues, pharmacy benefit managers transparency issues, Intellectual property, trade, and employment issues, 340B program, generally; S. 1040, Drug Competition Enhancement Act; H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 4317, PBM Reform Act of 2025; H.R. 5256, 340B ACCESS Act;" S. 3345 - "PBM Price Transparency and Accountability Act."
Client expense: — · Firm income: $60,000
Matched citations: S. 3345
PBM Price Transparency and Accountability Act
2026 · first_quarter · Firm: DAVE KOLBE CONSULTING
S.3345 - PBM Price Transparency and Accountability Act - Support comprehensive reform that addresses the entire healthcare supply chain. PBM practices drive up out-of-pocket costs for union members and working families.
Client expense: — · Firm income: $30,000
Matched citations: S.3345
Source: Senate LDA